BPC-157 Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on BPC-157 for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

BPC-157 is classified as a Pentadecapeptide derived from gastric juice protein BPC. Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | BPC-157 | | --- | --- | | Classification | Pentadecapeptide derived from gastric juice protein BPC | | Serum half-life | Reported serum half-life of approximately 4–6 hours in rodent models (intramuscular and subcutaneous), with rapid plasma clearance but extended local tissue retention. | | Tmax | Tmax ~30–60 minutes for subcutaneous and intramuscular routes in published animal pharmacokinetic studies. | | Validated routes | Subcutaneous, intramuscular, intragastric (oral) — oral stability is unusual among research peptides and is attributed to the BPC parent sequence. | | Bioavailability | Subcutaneous bioavailability ~70–100% in animal models; oral bioavailability reduced but pharmacologically active in published GI repair models. | | Clearance | Predominantly renal and hepatic clearance of degradation fragments; no parent peptide accumulation has been reported in published rodent multi-dose studies. |

Serum Half-Life

Reported serum half-life of approximately 4–6 hours in rodent models (intramuscular and subcutaneous), with rapid plasma clearance but extended local tissue retention.

Tissue vs Serum

Local tissue half-life appears longer than serum due to receptor-mediated retention at sites of injury and along the gut–brain axis.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For BPC-157, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax ~30–60 minutes for subcutaneous and intramuscular routes in published animal pharmacokinetic studies.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous, intramuscular, intragastric (oral) — oral stability is unusual among research peptides and is attributed to the BPC parent sequence.

Bioavailability across routes: Subcutaneous bioavailability ~70–100% in animal models; oral bioavailability reduced but pharmacologically active in published GI repair models.

Clearance & Metabolism

Predominantly renal and hepatic clearance of degradation fragments; no parent peptide accumulation has been reported in published rodent multi-dose studies.

Key Pharmacokinetic Takeaways

• Pentadecapeptide (15 amino acids) with unusual oral stability versus most research peptides
• Plasma half-life is short, but pharmacological activity persists due to receptor-mediated local retention
• Frequently dosed twice daily in research protocols to maintain steady-state exposure
• Subcutaneous and intramuscular routes show comparable AUC in animal PK data

Frequently Asked Questions

What is the half-life of BPC-157? Reported serum half-life of approximately 4–6 hours in rodent models (intramuscular and subcutaneous), with rapid plasma clearance but extended local tissue retention.

How quickly does BPC-157 reach peak concentration? Tmax ~30–60 minutes for subcutaneous and intramuscular routes in published animal pharmacokinetic studies.

Which routes of administration are validated in published research? Subcutaneous, intramuscular, intragastric (oral) — oral stability is unusual among research peptides and is attributed to the BPC parent sequence.

Does BPC-157 accumulate with repeat dosing? Predominantly renal and hepatic clearance of degradation fragments; no parent peptide accumulation has been reported in published rodent multi-dose studies. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for BPC-157? Subcutaneous bioavailability ~70–100% in animal models; oral bioavailability reduced but pharmacologically active in published GI repair models.

Related Research

• Reconstitution & storage protocols — see the BPC-157 reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the BPC-157 dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the BPC-157 mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*